Latest ArticlesGut-lung axis is an important endocrine regulatory axis in the human body which can influence and regulate the progression of chronic obstructive pulmonary disease (COPD). The gut-lung axis changes in COPD patients, which are reflected in the changes of lung microbes, gut microbes, and gut-lung axis immune modulating network. In gut-lung axis, components of gut microbes, crosstalk of microbes in gut and lung, microbe metabolites of gut microbes can all result in the exacerbation of COPD. However, clinical evidence indicates that the diversity of lung microbes cannot completely cause exacerbation of COPD, which may be related to the poor stability of lung microbes in COPD patients. Mechanisms of gut-lung axis on COPD progression include: the bacterial metabolite pathway and the immunity pathway, which further includes innate and adaptive immunity modulation and inflammatory agent cascades. In addition, there are still mucous immunity modulation and cytology modulation.
Chronic obstructive pulmonary disease (COPD) is a common clinical chronic airway disease. Although the existing treatment strategies can effectively control and relieve the symptoms of the disease, the disease is difficult to recover. New approaches are required to prevent the progress of the disease and reverse lung function deterioration. With the development of the gut-lung axis research in recent years, the study of prevention and treatment of COPD through intervention of the gut microbiome is gradually advancing. This article reviewed the research progress on regulating gut microbiome to treat COPD, aiming to explore new ideas for COPD prevention and provide direction for further clinical research and application of therapies based on the lung-gut axis.
Chronic obstructive pulmonary disease (COPD) is a common, preventable and treatable disease. Inspiratory muscle training (IMT), as a common method of pulmonary rehabilitation in patients with COPD, can improve symptoms and quality of life. This article reviewed the relevant studies on IMT in patients with COPD at different disease stages, and expounded the relevant mechanism, implementation method and clinical application value, in order to provide reference for further IMT in patients with COPD.
To investigate the effect of saxagliptin on podocyte injury induced by high glucose by regulating the microRNA (miR)-23b-3p/early growth response factor (EGR)1 axis.
Human podocytes were divided into control group, high glucose group, high glucose+saxagliptin group, high glucose+saxagliptin+anti-miR-control group and high glucose+saxagliptin+anti-miR-23b-3p group. The expression of miR-23b-3p, EGR1 messenger RNA (mRNA), proliferation, apoptosis, reactive oxygen species (ROS), malondialdehyde (MDA), superoxide dismutase (SOD), interleukin (IL)-1β, IL-6, desmin, split pore membrane proteins (Podocin, Nephrin), B cell lymphoma-2 related X protein (Bax), Caspase-3 and EGR1 protein were detected, the targeting relationship between miR-23b-3p and EGR1 was verified.
Compared with control group, the expression level of miR-23b-3p, proliferation rate, SOD, Podocin and Nephrin in high glucose group were obviously decreased, while the expression of EGR1 mRNA and protein, apoptosis rate, IL-1β, IL-6, MDA, ROS, Caspase-3, Bax and desmin were increased (P<0.05). Compared with high glucose group, the expression level of miR-23b-3p, proliferation rate, SOD, Podocin and Nephrin in high glucose+saxagliptin group were obviously increased, while the expression of EGR1 mRNA and protein, apoptosis rate, IL-1β, IL-6, MDA, ROS, Caspase-3, Bax and desmin were decreased (P<0.05). Down-regulation of miR-23b-3p could attenuate the improvement of saxagliptin on podocyte injury (P<0.05). MiR-23b-3p negatively regulated the expression of EGR1.
Saxagliptin may reduce high glucose-induced apoptosis and injury of podocytes by up-regulating miR-23b-3p and negatively regulating EGR1.
To investigate the association between plasma advanced glycation end products (AGEs) and carotid-femoral pulse wave velocity (cf-PWV) and urine albumin/creatinine ratio (ACR) in adults with hypertension.
The study subjects were patients who went to Ruijin hospital, Shanghai Jiao Tong university school of medicine for ambulatory blood pressure monitoring. The general condition and medical history of the hypertensive patients were collected through questionnaire survey, the brachial artery blood pressure was measured by Omron upper arm sphygmomanometer (HEM-7051), fasting blood was collected to determine biochemical indexes, including total cholesterol, triacylglycerol, and fasting blood glucose, and plasma AGEs concentration was measured by enzyme-linked immunosorbent assay. Urine ACR and cf-PWV measured by SpygmoCor software were used as indicators of target organ damage in hypertension.
The mean age of the 175 subjects was (51.23±11.38) years old, of which 78 were male (44.57%), accounting for 44.57%. The plasma AGEs level was higher in males compared to females [(7.80±6.37)μg/ml vs (4.41±3.62)μg/ml, P<0.001]. In terms of target organ damage, urinary ACR level in males was lower compared to females [(1.18±0.70) mg/mmol vs (2.10±2.17) mg/mmol, P<0.001]. There was no significant difference in cf-PWV (P=0.27). Before adjusting for related risk factors, plasma AGEs concentrations were positively correlated with fasting glucose (r=0.163, P=0.030), blood creatinine (r=0.219, P=0.003), and urinary ACR (r=0.150, P=0.046), and negatively correlated with high density lipoprotein cholesterol (r=-0.206, P=0.006). There was no significant correlation with cf-PWV (r=0.101, P=0.182). Multivariate stepwise linear regression analysis revealed that after adjustment for relevant risk factors, urinary ACR increased by 2.2% for each 1 μg/ml increase in plasma AGEs (P=0.023). There was no significant change in cf-PWVP (P=0.738).
Plasma AGEs concentration is an independent risk factor for the urinary ACR.
To explore the possible relationships between hypertension, proteinuria, gender, body mass, height, and other factors in the adolescent population by analyzing data on blood pressure, height, body mass, and urinary protein in 1 748 adolescents aged 11 to 17.
SPSS22.0 was used as the statistical analysis software. The statistical methods involved χ2 test, t-test, one-way analysis of variance, binary and multiple logistic regression.
A total of 1 748 adolescents aged between 11 and 17 from four middle schools in Shanghai were analyzed. The analysis found that the risk of hypertension in children aged 11 - 13 was 1.69 times higher than that of adolescents aged 14 - 17, and the incidence of grade 2 hypertension was 2.13 times higher. The risk of normal high blood pressure in women was 1.54 times higher than that in men, and the incidence of abnormal blood pressure in lean and normal individuals was significantly lower than that in obese individuals. The positive rate of urinary albumin/creatinine ratio (UACR) was affected by gender, age and blood pressure. The risk of women was 3.27 times higher than that of men, and the risk of children was 1.63 times higher than that of adolescents. Grade 2 hypertension significantly increased UACR positivity rate, but other blood pressure levels did not show significant differences.
There is a certain correlation between adolescent blood pressure levels and age, body mass index grading and gender. The positive rate of UACR is related to gender, age group and abnormal blood pressure, but only grade 2 hypertension increases the risk of UACR positivity.
To explore the effect of tirofiban combined with sodium nitroprusside in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI).
The clinical data of 97 patients with AMI who underwent PCI in our hospital from June 2019 to June 2022 were retrospectively analyzed, and the patients were divided into tirofiban group (n=48, tirofiban) and combination group (n=49, tirofiban combined with sodium nitroprusside) according to different medication regiments during PCI. Immediate postoperative blood flow improvement, ST segment regression at 2 h after surgery, serum cardiac troponin (cTn) I level before and after surgery, indexes of cardiac function before and after surgery [left ventricular end-diastolic diameter (LVEDD) and left ventricular ejection fraction (LVEF)] and the incidence of major adverse cardiac event (MACE) within 3 months after surgery were compared between the two groups.
The blood flow improvement rate and ST segment regression rate in the combination group were 97.96% and 95.92%, respectively, which were obviously higher than those in the tirofiban group (87.50% and 83.33%)(P<0.05). On the 3rd day after operation, the level of serum cTnI in the two groups were lower than those before operation (P<0.05), and the combination group was obviously lower than the tirofiban group (P<0.05). One month after operation, the LVEDD in both groups were lower than those before operation (P<0.05), and the LVEF were higher than those before operation (P<0.05), and the above cardiac function indexes in the combination group were obviously better than those in the tirofiban group (P<0.05). The incidence of MACE in the combination group was obviously lower (4.08%) than that in the tirofiban group (18.75%)(P<0.05).
Combined application of tirofiban and sodium nitroprusside during PCI in patients with AMI can effectively promote ST segment regression and coronary blood flow recovery, obviously improve cardiac function, and significantly reduce serum cTnI level and the risk of MACE.
To analyze retrospectively the effects of advanced age and diabetes mellitus (DM) on nucleic acid outcome of 2019 novel coronavirus (2019-nCoV).
A total of 748 cases of 2019-nCoV asymptomatic infection or mild patients who were positive for nucleic acid screening were collected from Fuchang road shelter, Baoshan district, Shanghai in April 2022. The effects of age and DM on the number of days of negative nucleic acid transformation were analyzed.
The number of days for nucleic acid to turn negative was (6.96±3.15) d for patients <40 years old (269 cases), (6.92±3.24)d for patients 40 – 50 years old (173 cases), (7.33±3.22)d for patients 50 - 60 years old (167 cases), (7.48±2.88)d for patients 60 - 70 years old (131 cases), (8.25±5.92)d for patients over 70 years old (8 cases). The difference was not statistically significant (P>0.05). The number of days for nucleic acid to turn negative was (7.57±3.29)d for patients with DM (113 cases), (7.06±3.16)d for patients without DM (635 cases), with no statistical significance (P>0.05).
There is no significant correlation between age, DM history, and the number of days of negative nucleic acid transformation in 2019-nCoV asymptomatic infected patients or mild patients, simply considering the age or combined DM can not predict the time of negative nucleic acid transformation.
To explore the effects of roxadustat combined with high-flux hemodialysis (HFHD) on calcium and phosphorus metabolism and total iron binding capacity (TIBC) in patients with chronic kidney disease (CKD).
A total of 80 CKD patients diagnosed with HFHD in the department of nephrology, Harbin the first hospital from January 2021 to December 2022 were selected and divided into control group and observation group according to random number table method, with 40 cases in each group. The control group received recombinant human erythropoietin combined with HFHD, and the observation group received roxadustat combined with HFHD. Efficacy, anemia related factors [hematocrit (HCT), hemoglobin (Hb)], iron metabolism related factors [TIBC, transferrin (TRF), TRF saturation (TSAT)], calcium and phosphorus metabolism related factors [serum calcium, serum phosphorus, parathyroid hormone (PTH)], serum inflammatory factors [tumor necrosis factor (TNF)-α, interleukin (IL)-6, C-reactive protein (CRP)], and the incidence of adverse reactions were compared between the two groups.
The total effective rate of observation group was higher than that of control group (92.50% vs 75.00%, P<0.05). The incidence of adverse reactions in the observation group was lower than that in the control group (7.50% vs 20.00%, P<0.05). The levels of Hb, HCT, TIBC, TRF and TSTA in observation group were higher than before treatment (P<0.05), and the levels in observation group were higher than those in control group (P<0.05). The levels of serum calcium, serum phosphorus, PTH, TNF-α, IL-6 and CRP in observation group were all decreased (P<0.05), and the levels in observation group were lower than those in control group (P<0.05).
Roxadustat combined with HFHD can significantly improve iron metabolism, calcium and phosphorus metabolism, anemia and inflammation in patients with CKD, with good safety.
To compare the efficacy and safety of azithromycin and minocycline hydrochloride in the treatment of female Mycoplasma infection in genital tract.
A retrospectively study was conducted on Mycoplasma culture and drug sensitivity of patients treated in our center from 2019 to 2021. One hundred and thirty-six patients with Mycoplasma infection in genital tract in our center in April to December 2021 were selected and divided into control groups and observation group, the control groups were given azithromycin for 5 or 7 days, and the observation group was given minocycline hydrochloride for 10 days, respectively, and then compared the effectiveness and safety indicators.
The observation group was better than the two control groups in mean therapeutic effect, incidence of drug resistance and pathogen clearance rate (P<0.05). There was no statistically significant difference in all aspects between control group 1 and control group 2 (P>0.05).
Minocycline hydrochloride has better efficacy, lower drug resistance rate and higher safety in treating genital Mycoplasma infection. There was no significant difference between the 5-day and 7-day methods of azithromycin in all respects.